FindTrial
Sign In

Efficacy of Ayush medicine NOQ19 in treatment of COVID-19 patients

A randomized, double blind, placebo controlled, trial to determine the therapeutic efficacy of Ayush medicine NF2 in treatment of symptomatic COVID-19 patients along with standard allopathic treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039370
Enrollment
100
Registered
2022-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Sriveda Sattva Private limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hospitalized or in home isolation adult patient aged >18 years Confirmed COVID-19 infection (RT ââ?¬â??PCR- Upper respiratory tract nasopharyngeal and oropharyngeal swab. mild and moderate Symptomatic COVID 19 infection with or without comorbidities Willingness to participate in the study Indian nationals

Exclusion criteria

Exclusion criteria: Age less than 18 years Pregnancy and Lactation Moribund state in which death is perceived to be imminent (�48 hours) Patient not willing to participate in the study Participation in any other clinical study

Design outcomes

Primary

MeasureTime frame
To evaluate the effect of NF2 in COVID 19 patients as time to become COV2 RT-PCR negative, duration of hospital stay, time to resolution of symptomsTimepoint: 7 days for each participant—

Secondary

MeasureTime frame
Effect of NF2 therapy on laboratory parameters - CBC, CRP, LFT, KFTTimepoint: Entry and Exit—

Countries

India

Contacts

Public ContactDr Vimal Narayanan

Government Institute of Medical Science

dranurag23@gmail.com9415061563

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026